chart. Yesterday, the price change of the stock pointed 0.00%, though its traded volume remained over 1 million shares. Now the question is, what’s the next move?The last announcement by Advaxis was released a couple of days ago, and it was an update on its upcoming science conference call. The science update will discuss the new findings of the company’s immunotherapy, which suppresses the immune-protection tumors recruit to defeat immune attacks. According to the announcement, the update call must have been held yesterday and a link to the conference should be posted on the company’s official website “on or before Thursday, December 23, 2010”. Most probably, now investors are waiting for the conference details before they make up their minds.[BANNER]
Advaxis, Inc. is a biotechnology company that uses the bioengineered bacterium Listeria monocytogenes to activate the immune system to treat cancer, infectious disease or allergic syndromes. As already reported on hotstocked.com, in October ADXS was climbing up due to some positive news on its cervical dysplasia study, though the results of the study are to be reported next September.
Meanwhile, the financial condition of Advaxis is still quite discouraging. In November, Advaxis entered into a Note Purchase Agreements with some accredited investors, however, the company has already much higher liabilities than assets on its balance sheet and should search for additional cash to pay the huge losses. While in the meantime, the management team expects the losses to continue.
